Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
Abstract Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since ea...
Main Authors: | Mariana Escamilla-Cruz, Mario Magaña, Sabrina Escandón-Perez, Omar Yaxmehen Bello-Chavolla |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-07-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-00974-4 |
Similar Items
-
Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
by: Hyun Hwan Sung, et al.
Published: (2019-05-01) -
Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy
by: Norma Marigliano, et al.
Published: (2012-01-01) -
Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection
by: Juan Morote, et al.
Published: (2024-02-01) -
Pharmacotherapy of androgenetic alopecia – a literature review
by: Marcin Tyszkiewicz, et al.
Published: (2022-11-01) -
Post-finasteride syndrome,
by: Ana Francisca Junqueira Ribeiro Pereira, et al.
Published: (2020-07-01)